Effectiveness, safety, and functional long-term outcomes (n=138)
| 1-year follow-up | 3-year follow-up† | |
| Primary effectiveness outcome | 106 (76.8) | 108 (78.3) |
| Occlusion status: Raymond–Roy | ||
| Complete occlusion (1) | 113 (81.9) | 115 (83.3) |
| Residual neck (2) | 3 (2.2) | 7 (5.1) |
| Residual aneurysm (3) | 22 (15.9) | 16 (11.6) |
| Occlusion status: mCSC | ||
| Complete occlusion (1/1A/1B) | 113 (81.9) | 118 (85.5) |
| Residual neck (2) | 3 (2.2) | 1 (0.7) |
| Aneurysm size reduction (3A/5/5A) | – | 15 (10.8) |
| Residual aneurysm (3/3C) | 22 (15.9) | 1 (0.7) |
| No consecutive follow-up for classification | – | 3 (0.9) |
| Target aneurysm retreatment | 4 (2.9) | 7 (5.0) |
| Target aneurysm recurrence | 0 | 1 (0.7) |
| Stenosis >50% | 4 (2.9) | 5 (3.6) |
| Primary safety outcome* | 3 (2.2) | 4 (2.9) |
| Functional independence (mRS ≤2) | 137/139 (98.6) | 127/130 (97.7) |
Data are n (%) or n/N (%).
*Defined as major stroke in the supplied territory or neurologic death; three events occurred within the first year, and one within the second year.
†In cases where 3-year digital subtraction angiography (DSA) control was not available, last observation carried forward of 2-year DSA was used. The latest follow-up is used for the mCSC.
mCSC, modified Cekirge–Saatci classification; mRS, modified Rankin Scale.